You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 205061 - 205070 of 207712 results
  1. High-Speed, Mode-Hop Insensitive SCI Source for Low Coherence Wavefront Probe for Nanometer Level Free-Form Metrology

    SBC: APRE INSTRUMENTS INC            Topic: S2

    Free-form optics promise improved optical system performance in all areas of imaging and illumination optics. Metrology tools with sufficient accuracy nbsp;and manufacturing throughputs are limiting the adoption of free-form optics and their advantages, including meeting NASArsquo;s goal of free-form X-Ray optics. The low coherence probe has demonstrated the potential to provide the metrology requ ...

    SBIR Phase I 2020 National Aeronautics and Space Administration
  2. Deployable Wound Care Products to Decrease Preventable Death Outcomes by Mitigating Infection on Battlefield and through Long Term Care

    SBC: KERICURE INC.            Topic: DHA201D001

    One of the greatest threats to an injured warfighter is infection. Exposure to dangerous pathogens carries a life-threatening risk, but it can also have severe morbidity consequences including sepsis, amputation, lengthy hospital stays and years of battling the infection. Field injuries are especially at risk, where dirt, shreds of the soldier’s clothing and other debris can infiltrate the wound ...

    SBIR Phase II 2022 Department of DefenseDefense Health Agency
  3. Ruggedized Spray on Antimicrobial Wound Dressing for Treatment of Multiple Sulfur Mustard-Induced Dermal Injuries in Theater to Mitigate Infection, Pain and Promote Healing

    SBC: KERICURE INC.            Topic: CBD212005

    Field Shield Wound Dressing (FSWD) is a novel wound dressing that takes an innovative approach to addressing major wounds, both in prolonged field care and throughout the continuum of care. It is the first wound dressing to combine an effective broad spectrum antimicrobial (nanosilver) with a local anesthetic (lidocaine) in a simple to apply point-and-spray wound dressing. A patented polyacrylate ...

    SBIR Phase I 2022 Department of DefenseOffice for Chemical and Biological Defense
  4. Deployable Wound Care Products to Decrease Preventable Death Outcomes by Mitigating Infection on Battlefield and through Long Term Care

    SBC: KERICURE INC.            Topic: DHA201D001

    The work effort in this Sequential Phase II supports the DHA objective of managing large surface area burn wounds in austere and prolonged field care (PFC) environments. KeriCure Medical’s spray on wound dressing technology, to be marketed under the brand name Field Shield, has been optimized to support combat casualty care’s efforts to improve management of large numbers of burn casualties at ...

    SBIR Phase II 2023 Department of DefenseDefense Health Agency
  5. Open Call for Science and Technology Created by Early-Stage (e.g. University) Teams

    SBC: 4TH PHASE TECHNOLOGIES, INC.            Topic: AF19BT001

    Durable and robust large-area ultrathin CNT sheets can be produced from pristine CNT sheets following proprietary CNT purification and densification processes. The resulting CNT sheets are free-standing, flexible, durable, robust, ultrathin (< 5 µm) and lightweight (~6 g per m2). They withstand corrosion and heat and are superior at shielding EMI (effectiveness >= 55 dB in the X band).

    STTR Phase I 2019 Department of DefenseAir Force
  6. Not Available

    SBC: CIVATECH ONCOLOGY, INC.            Topic: NCI

    The use of LDR brachytherapy after sub-lobar lung resection is the focus of a phase III NCI sponsored trial. Early clinical results from independent studies suggest that brachytherapy enables a singificant reduction in local recurrence rates versus surgery alone. Civatech Oncology and Allegheny General Hospital propose to design and fabricate a bio-absorbable, 2-dimensional sheet brachytherapy sou ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. IGF::OT::IGF OTHER FUNCTIONS DEVELOPMENT OF A UNI-DIRECTIONAL BRACHYTHERAPY DEVICE FOR THE TREATMENT OF NON-SMALL-CELL LUNG CANCER

    SBC: CIVATECH ONCOLOGY, INC.            Topic: NCI

    According to the American Cancer Society 220,000 men and women in the U.S. develop lung and bronchial cancer every year and 147,000 die of the disease. Of lung cancer patients, 85% present with non-small-cell lung cancer and 16.7% of these will present with localized disease. Note that lung cancer is very difficult to treat. The five year survival for localized disease is 52%, the five year surviv ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Pancreatic Cancers

    SBC: CIVATECH ONCOLOGY, INC.            Topic: 102

    CivaTech Oncology s mission is to provide improved radiation therapy directly to localized tumors The Company has developed a novel polymer encapsulated membrane like radiation source that emits radiation on only one side of the device the CivaSheet This directional source is compatible with open and minimally invasive surgical techniques and has FDA clearance to be used as primary or combin ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Pancreatic Cancers

    SBC: CIVATECH ONCOLOGY, INC.            Topic: 102

    CivaTech Oncology s mission is to provide improved radiation therapy directly to localized tumorsThe Company has developed a novelpolymer encapsulatedmembrane like radiation source that emits radiation on only one side of the devicethe CivaSheetThis directional source is compatible with open and minimally invasive surgical techniques and has FDA clearance to be used as primary or combined cancer t ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Clinical evaluation of the novel uni directional Pd CivaSheet for Lung Cancer

    SBC: CIVATECH ONCOLOGY, INC.            Topic: 102

    CivaTech Oncology s mission is to provide improved radiation therapy directly to localized tumors The Company has developed a novel polymer encapsulated membrane like radiation source that emits radiation on only one side of the device the CivaSheet This directional source is compatible with open and minimally invasive surgical techniques and has FDA clearance to be used as primary or combin ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government